The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

Professor Yvonne Bryson of the University of California Los Angeles described the new case at the conference and an accompanying press briefing. The middle-aged (post-menopausal) woman, a participant ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

Scientists from the pharmaceutical company Merck have published the first detailed data about a subset of the familiar non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs that, in addition to ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

The British HIV Association (BHIVA) conference in Gateshead this week heard the results of the first year’s rollout of opt-out testing for HIV and hepatitis B and C for all patients attending ...

A man dubbed the 'Geneva patient' appears to be the latest person cured of HIV after a stem cell transplant for cancer treatment. Unlike the other five known cases, however, he received stem cells ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

Now, in what its authors describe as an “exploratory and descriptive study”, figures from different agencies have been pulled together to paint a picture of HIV in this vast country. The analysis, by ...

By 2022, half of all patients eligible for this analysis were taking reduced-drug treatment. In people taking three-drug daily treatment in 2015, there was no change in the proportion who were virally ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...